| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
and Ki-67 Expression

From the Departments of Cellular and MolecularPathology*
and PublicHealth,
University of Liverpool, Liverpool,United Kingdom
The hypothetical multistep model for breast carcinogenesis
indicates that invasive carcinoma arises via a series of intermediate
hyperplastic lesions through various grades of atypia to in
situ and invasive carcinoma. Non-atypical hyperplasia
[hyperplasia of usual type (HUT)] is a nonobligate precursor of
breast cancer. Although its further morphological subclassification is
unlikely, refining is more likely to depend on defining
biological markers of risk. Having assembled a cohort of benign
proliferative breast lesions of known outcome, we studied the
expression of estrogen receptor-
(ER-
) and Ki-67 using
morphometric image analysis as well as dual-labeled immunofluorescence
in HUT foci and in surrounding normal lobules of 25 patients that
progressed to breast cancer and 19 controls. Those patients that
progressed to breast cancer (cases) showed significantly higher ER-
[median, 57.00% of cells within individual HUT foci;
interquartile range (IQ), 33.48 to 67.78] and Ki-67
(median, 3.82%; IQ, 0.85 to 11.28) expression in their
HUT foci compared with controls (ER-
median, 30.27%;
IQ, 19.75 to 52.50 and Ki-67 median, 0.77%;
IQ, 0.0458 to 1.72, P = 0.008 and
<0.001). No significant difference in expression of dual-stained cells
was found between cases and controls. Although normal lobules from
cases showed higher ER-
expression compared with controls,
this was not statistically significant. Our data point to a previously
undescribed hormone-dependent pathway in this particular group of
breast neoplasms and suggest the possibility of selective hormonal
therapy to suppress the proliferative potential of these benign but
high-risk breast lesions. The findings of this study might have
important implications for improving breast cancer screening and
management strategies.
This article has been cited by other articles:
![]() |
D. M. Euhus, D. Bu, S. Milchgrub, X.-J. Xie, A. Bian, A. M. Leitch, and C. M. Lewis DNA Methylation in Benign Breast Epithelium in Relation to Age and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1051 - 1059. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Sundar, V. Kerekatte, C. N. Equinozio, V. B. Doan, L. F. Bjeldanes, and G. L. Firestone Indole-3-Carbinol Selectively Uncouples Expression and Activity of Estrogen Receptor Subtypes in Human Breast Cancer Cells Mol. Endocrinol., December 1, 2006; 20(12): 3070 - 3082. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Fabian and B. F. Kimler Mammographic Density: Use in Risk Assessment and as a Biomarker in Prevention Trials J. Nutr., October 1, 2006; 136(10): 2705S - 2708S. [Full Text] [PDF] |
||||
![]() |
M. Cazzaniga, G. Severi, C. Casadio, L. Chiapparini, U. Veronesi, and A. Decensi Atypia and ki-67 expression from ductal lavage in women at different risk for breast cancer. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1311 - 1315. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bhandare, R. Nayar, M. Bryk, N. Hou, R. Cohn, N. Golewale, N. P. Parker, R. T. Chatterton, A. Rademaker, and S. A. Khan Endocrine Biomarkers in Ductal Lavage Samples from Women at High Risk for Breast Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2620 - 2627. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Arpino, R. Laucirica, and R. M. Elledge Premalignant and In Situ Breast Disease: Biology and Clinical Implications Ann Intern Med, September 20, 2005; 143(6): 446 - 457. [Abstract] [Full Text] [PDF] |
||||
![]() |
S A Khan, D Bhandare, and R T Chatterton Jr The local hormonal environment and related biomarkers in the normal breast Endocr. Relat. Cancer, September 1, 2005; 12(3): 497 - 510. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bhandare, S. A. Khan, C. J. Fabian, and Q. J. Khan Ki-67 Expression in Benign Breast Ductal Cells Obtained by Random Periareolar Fine Needle Aspiration Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2278 - 2279. [Full Text] [PDF] |
||||
![]() |
Q. J. Khan, B. F. Kimler, J. Clark, T. Metheny, C. M. Zalles, and C. J. Fabian Ki-67 Expression in Benign Breast Ductal Cells Obtained by Random Periareolar Fine Needle Aspiration Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 786 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Muller-Decker, I. Berger, K. Ackermann, V. Ehemann, S. Zoubova, S. Aulmann, W. Pyerin, and G. Furstenberger Cystic Duct Dilatations and Proliferative Epithelial Lesions in Mouse Mammary Glands upon Keratin 5 Promoter-Driven Overexpression of Cyclooxygenase-2 Am. J. Pathol., February 1, 2005; 166(2): 575 - 584. [Abstract] [Full Text] [PDF] |
||||
![]() |
M P A Davies, P A O'Neill, H Innes, D R Sibson, W Prime, C Holcombe, and C S Foster Correlation of mRNA for oestrogen receptor beta splice variants ER{beta}1, ER{beta}2/ER{beta}cx and ER{beta}5 with outcome in endocrine-treated breast cancer J. Mol. Endocrinol., December 1, 2004; 33(3): 773 - 782. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Fabian, B. F. Kimler, J. Anderson, O. W. Tawfik, M. S. Mayo, W. E. Burak Jr., J. A. O'Shaughnessy, K. S. Albain, D. M. Hyams, G. T. Budd, et al. Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator Clin. Cancer Res., August 15, 2004; 10(16): 5403 - 5417. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Papantoniou, J. Koutsikos, M. Sotiropoulou, E. Mainta, D. Lazaris, S. Tsiouris, and C. Zerva Scintimammographic Findings of Phyllodes Tumor of the Breast in a Double-phase Study with Tc-99m (V)DMSA and Tc-99m MIBI: a Case Report Jpn. J. Clin. Oncol., July 1, 2004; 34(7): 429 - 431. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Fabian, B. F. Kimler, D. A. Brady, M. S. Mayo, C. H. J. Chang, J. A. Ferraro, C. M. Zalles, A. L. Stanton, S. Masood, W. E. Grizzle, et al. A Phase II Breast Cancer Chemoprevention Trial of Oral {alpha}-Difluoromethylornithine: Breast Tissue, Imaging, and Serum and Urine Biomarkers Clin. Cancer Res., October 1, 2002; 8(10): 3105 - 3117. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |